

REMARKS

Reconsideration of this Application is respectfully requested.

Claims 1-6, 13-15, 20-21, and 26 are pending in the application, with 1 and 26 being the independent claims. The claim amendments are supported in the instant specification at pages 8, 11-14, and 16-17 and no new matter has been added.

Based upon the foregoing Amendments, attached Declaration, and following Remarks, the applicants respectfully request the Examiner reconsider all outstanding rejections, and that they be withdrawn.

Rejection under 35 U.S.C. § 112, 1st paragraph – Claims 13-14

Claims 13-14 stand rejected under 35 U.S.C. §112, 1st paragraph, as failing to comply with the written description requirement. The Examiner asserts that the specification and claims lack sufficient written description of the polynucleotide encoding the hybrid polypeptide; there is no description of the nucleic acids that must encode the hybrid polypeptide; the specification does not provide for the structure of the polynucleotide; and the specification does not provide a teaching of the entire structure, showing that nucleic acids were isolated at the time the invention was made.

Applicants respectfully traverse this rejection. The attached 37 C.F.R. §1.132 declaration is herewith submitted to traverse the rejection. As evident from the attached declaration, Dr. Rudolf Valenta attests to the fact that at the time the invention was made, the polynucleotide and polypeptide sequences for the timothy grass pollen allergens were available in the art. As evident from the Exhibits attached to the declaration, Phl p1 was disclosed in the Peterson, *et al.* reference in 1995, Phl p2 was disclosed in an article authored by Dr. Valenta in 1993, Phl p5 was disclosed in an article authored by Dr. Valenta in 1993, and Phl p6 was disclosed in an article authored by Dr. Valenta in 1999. Therefore, all of the timothy pollen sequences were known at the time the invention was made and prior to the filing date of the instant application.

Dr. Valenta also declares that one of ordinary skill in the art, armed with the instant specification, would understand the sequences used in the present invention. As evident from the specification, the applicants had isolated the nucleic acid sequences and had possession of the claimed hybrid polypeptides. The applicants describe the construction of the hybrid polypeptides in Examples 2 and 3 of the specification. Specifically, the specification sets forth the method of constructing the plasmids and the method of expressing and purifying the hybrid polypeptides. *See* Examples 2 and 3, pp. 11-14. The applicants also provide examples showing the assays used to determine the activity of the hybrid polypeptides in comparison to individual allergenic proteins. *See* Examples 4, 5, and 6, pp. 14-17. Therefore, the instant application satisfies the written description requirement for the claimed hybrid polypeptides and method for preparing hybrid polypeptides.

Applicants respectfully request reconsideration of this rejection and withdrawal of these grounds of rejection in view of the aforementioned remarks. Applicants submit that the pending claims satisfy the written description requirement.

Rejection under 35 U.S.C. § 112, 1st paragraph – Claims 1-6, 13-15, 20-21 and 26

Claims 1-6, 13-15, 20-21 and 26 stand rejected under 35 U.S.C. §112, 1st paragraph, as failing to comply with the written description requirement. The Examiner asserts that the claims drawn to the fragments thereof, wherein the fragments consist of amino acid sequences that fail to recite any associated function and that it is unclear how to define fragments thereof with respect to what amino acids must be comprised therein to acquire the appropriate fragments. Therefore, the Examiner asserts that the claims lack an adequate description of both the fragments thereof and the function of the polypeptide.

Applicants respectfully traverse this rejection. The claims have been amended to recite the associated function of inducing an antibody response as supported throughout the specification and in particular pages 8 and 16-17. The amino acids of the present

invention for the fragments, as described in the claims, are at least 8 consecutive amino acids that result in inducing an antibody response. The specification defines “allergenic proteins or fragments thereof” as comprising “modifications of the allergens wherein the sequence of the naturally occurring allergen has been slightly modified by substitutions of single amino acids or nucleotides whereby the allergenic potential has been substantially maintained.” *See* Specification, p. 2. Further, the specification specifically states that “when fragments of allergenic proteins are employed it is possible to prepare a hybrid polypeptide comprising only fragments which have an allergenic activity which is lower compared with the respective allergenic proteins from which they are derived.” *See* Specification, p. 3. The inventors continue on to explain that this lower allergenic activity could “be due to the destruction of epitopes by modified secondary or tertiary structure of the fragment compared with the full length protein.” *See* Specification, p. 3. The specification discloses the activity of various antigenic proteins and hybrid polypeptides illustrating that the applicants invented the hybrid polypeptide and had possession of the invention at the time the application was filed.

In *Vas-Cath v. Mahurkar*, 19 USPQ2d 1111, 1117 (Fed. Cir. 1991), the court states that the applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date, the applicant was in possession of the invention. In light of the declaration signed by Dr. Valenta, regarding the availability of the sequences for the allergenic proteins Phl p1, Phl p2, Phl p5, and Phl p6, one of ordinary skill in the art, aided by the instant specification, would understand the fragments thereof encompassed by the claims based upon the fact that the allergenic potential is maintained and the resulting hybrid polypeptide induces an antibody response. Therefore, the applicants have conveyed with clarity to those skilled in the art that they were in possession of the invention.

Applicants respectfully request reconsideration of this rejection and withdrawal of these grounds of rejection in view of the aforementioned remarks. Applicants submit that the pending claims satisfy the written description requirement.

Rejection under 35 U.S.C. § 102 (b) – Vrtala et al.

Claims 1-3, and 13-14 stand rejected under 35 U.S.C. §102(b) as being anticipated by Vrtala, *et al.* (1996, J. Allergy Clin. Immun., Vol. 97(3):781-787). The Examiner asserts that the reference teaches a hybrid polypeptide comprising at least two different allergenic proteins, specifically Phl p1 and Phl p2 and that these are the complete allergenic proteins as the cDNA used for encoding the mature protein. The Examiner also asserts that the reference teaches a polynucleotide, which encodes a polypeptide that meets the claimed limitations and a method for preparing a hybrid polypeptide using PCR technology comprising the same steps as recited by the instant claims.

Applicants respectfully traverse this rejection. "A claim is anticipated only if each and every element as set forth in the claim is found, either expressly or inherently described, in a single prior art reference." *Verdegaal Bros. v. Union Oil Co. of California*, 814 F.2d 628, 631, 2 USPQ2d 1051, 1053 (Fed. Cir. 1987). Therefore, if a prior art reference does not teach each and every claim element, it does not anticipate the claim.

The Vrtala, *et al.* reference does not teach a hybrid polypeptide as asserted by the Examiner. The 37 C.F.R. §1.132 declaration, herewith attached, attested to by Dr. Valenta states that Dr. Valenta is an author of the Vrtala, *et al.* reference and that it does not describe or teach a hybrid polypeptide using timothy grass pollens, but rather only teaches the allergens individually. As such, the reference does not teach each and every claim element and therefore is not anticipated by the Vrtala, *et al.* reference.

Applicants respectfully request reconsideration of this rejection and withdrawal of these grounds of rejection in view of the aforementioned remarks. Applicants submit that the pending claims are not anticipated.

CONCLUSION

All of the stated grounds of objection and rejection have been properly traversed, accommodated, or rendered moot. Applicants therefore respectfully request that the Examiner reconsider all presently outstanding rejections and that they be withdrawn. It is believed that a full and complete response has been made to the outstanding Office action and, as such, the present application is in condition for allowance. Applicants wish to expedite the prosecution process and if the Examiner believes, for any reason that personal communication will help expedite prosecution of this application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of this Response is respectfully requested.

Respectfully submitted,

REED SMITH, LLP

By: Toni-June Herbert
Toni-June Herbert
Reg. No. 34,348 *scit*

Date: Oct. 4, 2004

1301 K Street, N.W.
Suite 1100-East Tower
Washington, D.C. 20005
(202) 414-9200



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Linhart, et al.

Art Unit: 1645

Serial No. 10/026,914

Examiner: Jana A. Hines

Filed: 12/27/01

Atty. Docket: 966927.00006

For: Allergy Vaccines Containing Hybrid
PolypeptidesDECLARATION UNDER 37 C.F.R. § 1.132Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I, Dr. Rudolf Valenta, M.D., state that I am one of the named inventors in the above-referenced application, and hereby declare and state:

1. I have read the Office action mailed on July 2, 2004 in the above-referenced application.
2. I am one of the authors of the Vrtala, et al. reference (1996, J. Allergy Clin. Immun., Vol. 97(3):781-787) cited by Examiner Jana A. Hines in the Office action mailed on July 2, 2004.
3. The Vrtala, et al. reference does not describe or teach the production of a hybrid polypeptide and more specifically, does not describe or teach a hybrid polypeptide comprising two different allergenic proteins such as Phl p1 and Phl p2.
4. The Vrtala, et al. reference only reports the expression of the individual allergens.
5. The cDNA and amino acid sequences for the timothy grass pollen allergens described in the instant application and namely, Phl p1, Phl p2, Phl p5, and Phl p6, were available in the art at the time the invention was made and at the filing of the instant application, which is illustrated in Exhibits 1-4, herewith attached. Further, one of ordinary skill in the art, armed with the instant application, would understand the sequences of said allergens and the claimed hybrid polypeptide invention.

6. That all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that the statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patents ensuing thereon.

Date:

Sept 28, 2004

1301 K Street, N.W.
Suite 1100 - East Tower
Washington, DC 20005
Tel. 202-414-9200

Respectfully submitted,


Dr. Rüdolf Valenta, M.D.

A.o. Univ. Prof. Dr. R. VALENTA
Institut für Pathophysiologie, Universität Wien
AKH, Ebene 3 O
1090 Wien, Währinger Gürtel 18-20
Tel. (+43 1) 40400 - 5108, Fax - 5130

32256

PATENT TRADEMARK OFFICE



CGCTCAGGAGGACCTTCGCGCGTAGAGATCGGATCCCGCGCGGATTATATAGCTCGATCGATC1
 TTCTCTATATCCGCGCGATGGGATATACACACACACCGCGCGGATAGCATGACTGATCT7
 CCCCACCTTCTTCGATACGTCGCTTCTTCGATACGTCGCTTCTTCGATACGTCGCTTCTTCGAT
 CACAGACTTACGCTTCTTCGATACGTCGCTTCTTCGATACGTCGCTTCTTCGATACGTCGCTTCTTCG

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	Books
Search		Nucleotide	for			Go	Clear	
Limits		Preview/Index		History		Clipboard		Details
Display	default	Show	20	Send to	File	Get Subsequence	Features	

☐ 1: Z27090. P.pratense mRNA f...[gi:3901093]

Links

LOCUS PPRPHLP1X 1152 bp mRNA linear PLN 09-SEP-2004
 DEFINITION P.pratense mRNA for pollen allergen PhlpI.
 ACCESSION Z27090
 VERSION Z27090.1 GI:3901093
 KEYWORDS PhlpI; pollen allergen.
 SOURCE Phleum pratense (timothy grass)
 ORGANISM Phleum pratense
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Pooideae; Aveneae; Phleum.
 REFERENCE 1 (bases 1 to 1149)
 AUTHORS Petersen,A., Schramm,G., Bufe,A., Schlaak,M. and Becker,W.M.
 TITLE Structural investigations of the major allergen Phl p I on the
 complementary DNA and protein level
 JOURNAL J. Allergy Clin. Immunol. 95 (5 Pt 1), 987-994 (1995)
 MEDLINE 95270847
 PUBMED 7751520
 REFERENCE 2 (bases 1 to 1149)
 AUTHORS Petersen,A.
 TITLE Direct Submission
 JOURNAL Submitted (01-NOV-1993) Petersen A., Forschungsinstitut Borstel,
 Allergology, Parkallee 22, 23845 BORSTEL, Germany
 COMMENT On Nov 21, 1998 this sequence version replaced gi:414907.
 FEATURES
 source Location/Qualifiers
 1..1152
 /organism="Phleum pratense"
 /mol_type="mRNA"
 /strain="agrostideae"
 /isolate="24W28-7c"
 /db_xref="taxon:15957"
 /clone="p4"
 /cell_line="Phleum pratense pollen/charge 24W28-7c"
 /clone_lib="cDNA/38/10/ZAP/6a"
 gene 1..1152
 /gene="phlpI.p4"
 5'UTR 1..8
 /gene="phlpI.p4"
 CDS 9..800
 /gene="phlpI.p4"
 /codon_start=1
 /product="pollen allergen Phl pI"
 /protein_id="CAA81613.1"
 /db_xref="GI:3901094"
 /db_xref="GOA:Q40967"
 /db_xref="UniProt/TrEMBL:Q40967"
 /translation="MASSSSVLLVVALFAVFLGSAHGIPKVPVPGPNITATYGDKWLD
 KSTWYGKPTAAGPKDNGGACGYKDVDKPPFSGMTGCGNTPIFKSGRGCGSCFEIKCTK
 PEACSGEPVVVHITDDNEEPIAAYHFDLSGIAFGSMAKKGDEQKLSAGEVEIQFRRV
 KCKYPEGTVTFHVEKGSNPNYLALLVKFVAGDGDVVAVDIKEKGDKWIALKESWGA
 IWRIDTPEVLKGPFTVRYTTEGGTKGEAKDVIPEGWKADTAYESK"
 sig_peptide 9..77
 /gene="phlpI.p4"

mat peptide 78..79,
/gene="phlpI.p4"
/product="pollen allergen Phl pI"
/function="unknown"
3'UTR 801..1152
/gene="phlpI.p4"

ORIGIN

```
1 aagacaagat ggotttttcc tcatcggttc tgetgggtcgt ggcgctgttc gccgttttcc
61 tgggctctgc gcatggcatc cccaaggtcc cccccggccc gaacatcacg gcgacctacg
121 gcgacaagtg gctggacgcg aagagcacct ggtacggcaa gccgacggcc gccggtccca
181 aggacaacgg cggcgcggtgc ggggtacaagg acgtggacaa gcccccggtc agcggcatga
241 ccggctgcgg caacaccccc atcttcaagt ccggccgggg ctgcggctcc tgcttcgaga
301 tcaagtgcac caagcccgag gcctgctccg gcgagcccg ggtgggtccac atcaccgacg
361 acaacgagga gcccatcgcc gcgtaccact tcgacctctc cggcatcgcg ttcgggtcca
421 tggccaagaa gggcgacgag cagaagctgc gcagcgccgg cgaggtggag atccagttcc
481 gccgctcaa gtgcaagtac ccggagggca ccaaggtcac cttccacgtg gagaaggggt
541 ccaaccccaa ctacctggcg ctgctggtga agtttgtcgc cggcgacggc gacgtggtgg
601 cgggtggacat caaggagaag ggcaaggaca agtggatcgc gctcaaggag tcgtggggag
661 ccatctggag gatcgacacc ccggaggtgc tcaagggcc cttcacctgc cgctacacca
721 ccgagggcgg caccaagggc gaggccaagg acgtcatccc cgagggctgg aaggccgaca
781 ccgcctacga gtccaagtga acaatccatc catcaatgga tccttcacca cccctacgta
841 ccacttccgg caagttcaat tttgactcaa caagatcacc aataagttaa ccggtcggcc
901 acatctatat aggccagcgc aagctcctag catgttcatg ctacagagag gggaaatgcg
961 agagtaataa ctaatttgag gtcgagacct tgcgacttgc gaggtgtatg taggaggcaa
1021 ccaacaaaaa atggtttgtc ctccggccca cactcggacc gctttaattg tttatgtatc
1081 taagattggt catgtttatg aacatatata ttgtaataca taattttgtc cataaaccat
1141 cgattatata aa
```

//

Disclaimer | Write to the Help Desk
NCBI | NLM | NIH

Aug 20 2004 01:46:11

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Seq ID: 27 - 12 of 12



Nucleotide

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	Books
Search	Nucleotide	<input type="checkbox"/>	for	<input type="text"/>	<input type="button" value="Go"/>	<input type="button" value="Clear"/>		
Limits		Preview/Index		History		Clipboard		Details
Display	default	<input type="checkbox"/>	Show	20	<input type="checkbox"/>	Send to	File	<input type="checkbox"/>
						Get Subsequence		Features

□ 1: X74735. *P. pratense* mRNA ...[gi:398829]

Links

```

LOCUS      PPHLP5                      1192 bp      DNA      linear      PLN 21-APR-1997
DEFINITION P. pratense mRNA for PhlpV.
ACCESSION  X74735
VERSION    X74735.1   GI:398829
KEYWORDS   allergen.
SOURCE     Phleum pratense (timothy grass)
  ORGANISM Phleum pratense
            Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
            Pooideae; Aveneae; Phleum.
REFERENCE  1 (bases 1 to 1192)
  AUTHORS  Vrtala,S., Sperr,W.R., Reimitzer,I., van Ree,R., Laffer,S.,
            Mueller,W.D., Valent,P., Lechner,K., Rumpold,H., Kraft,D.,
            Scheiner,O. and Valenta,R.
  TITLE    cDNA cloning of a major allergen from timothy grass (Phleum
            pratense) pollen; characterization of the recombinant Phl pV
            allergen
  JOURNAL  J. Immunol. 151 (9), 4773-4781 (1993)
  MEDLINE  94014421
  PUBMED   7691956
REFERENCE  2 (bases 1 to 1192)
  AUTHORS  Vrtala,S.
  TITLE    Direct Submission
  JOURNAL  Submitted (17-AUG-1993) S. Vrtala, Institute of General &
            Experimental Pathology, Wahringner Guerel 18-20, AKH, 1090 Wien,
            AUSTRIA

```

```

FEATURES             Location/Qualifiers
     source            1..1192
                        /organism="Phleum pratense"
                        /mol_type="genomic DNA"
                        /db_xref="taxon:15957"
                        /clone="pUC 18"
                        /clone_lib="lambda gtl1-cDNA library"
     CDS             44..982
                        /codon_start=1
                        /product="Phlp5"
                        /protein_id="CAA52753.1"
                        /db_xref="GI:398830"
                        /db_xref="UniProt/TreMBL:Q40960"
                        /translation="MAVHQYTVALFLAVALVAGPAASYAADLGYGPATPAAPAAGYTP
ATPAAPAEAAPAGKATTEEQKLIKINAGFKAALAAAGVQPADKYRTFVATFGAASN
KAFAGEGLSGEPKGAAESSSKAALTSKLDAAYKLAYKATAGATPEAKYDAYVATLSEAL
RIIAGTLEHVAVKPAAEVKKVIPAGELQVIEKVDAAFKVAATAANAAPANDKFTVFEA
AFNDAIKASTGGAYESYKFI PALEAAVKQAYAATVATAPEVKYTVFETALKKAITAMS
EAQKAAPAAAATATATAAVGAATGAATAATGGYKV"
     sig_peptide    44..117
     mat_peptide    118..979

```

ORIGIN							
1	ccccatatct	tcccacctac	ggtacaaaaca	acagcaagca	gcaatggcgg	tgcaccagta	
61	cactgtggcg	ctgttctctg	ccgtggccct	cgtggcgggc	ccggccgcct	cctacggcgc	
121	cgatctcggt	tacggccccg	ccaccccgac	tgcggcgccc	gcggctcata	ccccgccac	
181	ccccgcgcgc	ccggccgaag	cggcgccagc	aggtaaagcg	acgaccgagg	agcagaagct	

241 gatcgagaag atcaacgCcg gcttcaagge ggccttgge gcgcgcgcg gogtccagcc
301 agcggacaag tacaggacgt tcgtcgcaac cttcggcgcg gcctccaaca aggccttcgc
361 ggagggcctc tcggggcgagc ccaagggcgc cgccgaatcc agctccaagg ccgcgctcac
421 ctccaagctc gacgccgcct acaagctcgc ctacaagaca gccgagggcg cgacgcctga
481 ggccaagtac gacgcctacg tcgccaccct aagcgaggcg ctccgcatca tcgccggcac
541 cctcgaggtc cacgccgtca agcccgcggc cgaggaggtc aaggatcatc ccgcgggca
601 gctgcaggtc atcgagaagg tcgacgccgc ctccaaggtc gctgccaccg ccgccaacgc
661 cgcccccgcc aacgacaagt tcaccgtctt cgaggccgcc ttcaacgacg ccatcaaggc
721 gagcacgggc ggcgcctacg agagctacaa gttcatcccc gccctggagg ccgcgctcaa
781 gcaggcctac gccgccaccg tcgccaccgc gccggaggtc aagtacactg tctttgagac
841 cgactgaaa aaggccatca ccgccatgtc cgaggcacag aaggctgcc aagccgcgc
901 cgctgccacc gccaccgcaa ccgcgcgcgt tggcgcggcc accggcgccg ccaccgcgc
961 tactggtggt taaaaagtct gatcaactcg cgaatagtat acatcaatca cgcacatata
1021 cgaccgtacg tatgtgtgca tgcattgccg tcgcgtcgag caattttgct gataattaat
1081 tcttgagttt ttcgttgcgt gcatccgcgc gttatagagc gcatgcacgc attgccattt
1141 gtgtataata atcaaatatc tgcaattcat ttatgaaaaa aaaaaaaaaa aa

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

SeqView: 398829



EGTCAGGA...GACTTCG...GCTAGAGATCGGATCCCGG...ATTATATAGCTCGATCGATC
 TTCTCTAT...GCGCG...ATGG...ATATACACACAC...GCGCGGATAGCATGACTGATCT
 CCCC...CTTCGCATACGTCT...GCGCGGATAGCATGACTGATCT
 CACAGAC...ACGCT...CTCACTTAACTAACCAATTCGCGAGCGGCGGCGGATCGCGGAG

Entrez	PubMed	Nucleotide	Protein	Genome	Structure	PMC	Taxonomy	Books
Search		Nucleotide	<input checked="" type="checkbox"/> for			Go	Clear	
Limits		Preview/Index		History		Clipboard		Details
Display	default	<input checked="" type="checkbox"/>	Show	20	Send to	File	Get Subsequence	Features

☐ 1: Y16959. Phleum pratense m...[gi:3004472]

Links

LOCUS PPY16959 474 bp mRNA linear PLN 11-OCT-1999
 DEFINITION Phleum pratense mRNA for Phl p6 IgE binding fragment, isolate c233.
 ACCESSION Y16959
 VERSION Y16959.1 GI:3004472
 KEYWORDS IgE binding protein.
 SOURCE Phleum pratense (timothy grass)
 ORGANISM Phleum pratense
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
 Pooideae; Aveneae; Phleum.
 REFERENCE 1
 AUTHORS Vrtala,S., Fischer,S., Grote,M., Vangelista,L., Pastore,A.,
 Sperr,W.R., Valent,P., Reichelt,R., Kraft,D. and Valenta,R.
 TITLE Molecular, immunological and structural characterization of Phl p6,
 a major allergen and P-particle-associated protein from Timothy
 grass (Phleum pratense) pollen
 JOURNAL J. Immunol.
 REFERENCE 2 (bases 1 to 474)
 AUTHORS Vrtala,S.
 TITLE Direct Submission
 JOURNAL Submitted (25-MAR-1998) S. Vrtala, Institute of General and
 Experimental Pathology, Wahringerguertel 18-20, AKH, 1090 Wien,
 AUSTRIA
 COMMENT Related sequence: Z27090.
 FEATURES
 source Location/Qualifiers
 1..474
 /organism="Phleum pratense"
 /mol_type="mRNA"
 /isolate="c233"
 /db_xref="taxon:15957"
 /tissue_type="pollen"
 /clone_lib="lambda gt11"
 /dev_stage="mature"
 CDS
 <1..174
 /codon_start=1
 /product="Phl p6 IgE binding fragment"
 /protein_id="CAA76560.1"
 /db_xref="GI:3004473"
 /db_xref="GOA:O65868"
 /db_xref="UniProt/TrEMBL:O65868"
 /translation="SKAPQLVPKLDEVYNAAYNAADHAAPEDKYAEFVLHFSEALHII
 AGTPEVHAVKPGA"

ORIGIN

```

1 tcaaaggcgc cccagctggt cccaagctc gatgaagtct acaacgcgc ctacaatgct
61 gccgatcatg ccgccccaga agacaagtat gaagccttcg tccttcaatt ttccgaggct
121 ctccacatca tcgccggtac ccccgaggct cacgctgtca agcccggcgc gtagttgttc
181 agcacggtca agatccttga cagcgtcgct gccaccggcg ctgcagccaa cactgccagt
241 ggctaaaaaa ttcgactagc tccttcatac aatgaatata catgtatcat tcaaacatac
301 tactgtacag tatgtgcatg acctagcggc gagcattttt tttatgatta atcttttata
361 catgggcgtg atcgagcgtg tgcatatgtg taataattaa ttttttattt tgatttgaaa
421 ttgtaatcct gataagaaat gcgattaagt ccatttatga aaaaaaaaaa aaaa

```

//

[Disclaimer](#) | [Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)

Seq. ID: 3004472